


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. **(withdrawn)** A compound represented by formula (I)




wherein A is a cyclic group which may have a substituent(s);

X, Y and Z are each independently a single bond or a spacer of which main chain has an atom number of 1-3; and

B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s),

a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

2. **(withdrawn)** The compound according to claim 1, which is represented by formula (I-1)




wherein ring A<sup>1</sup> is a di-, tri-, or tetra-nitrogen-containing heterocyclic ring, the other symbols have the same meanings as those defined in claim 1, and wherein ring A<sup>1</sup> is not 2,3,4,5-tetrahydro-1H-1-benzazepine, 1,2,3,4,5,6-hexahydro-1-benzazepine, 2,3,4,5-

tetrahydro-1,5-benzoxazepine, 6,7,8,9-tetrahydro-5H-pyrid[2,3-d]azepine or 5,6,7,8-tetrahydro-4H-thieno[3,2-d]azepine.

3. **(withdrawn)** The compound according to claim 2, wherein ring A<sup>1</sup> is a tri-, or tetra-nitrogen-containing heterocyclic ring.

4. **(withdrawn)** The compound according to claim 3, which is represented by formula (I-2)



wherein ring A<sup>2</sup> is a mono-nitrogen-containing heterocyclic ring;

ring A<sup>3</sup> is a mono-carbocyclic ring or mono-heterocyclic ring;

plural R<sup>1</sup>'s are each independently a substituent, and when R<sup>1</sup>'s are plural, two R<sup>1</sup>'s may be together to form cyclic group which may have a substituent(s);

R<sup>2</sup> is a hydrogen atom or a substituent;

t and s are each independently 0 or an integer of 1-5, and the sum of t and s is 5 or less;


J<sup>1</sup> is a single bond, a carbon atom which may have a substituent(s), a nitrogen atom which may have a substituent(s), an oxygen atom or a sulfur atom which may be oxidized;

J<sup>2</sup>, J<sup>3</sup>, J<sup>4</sup> and J<sup>5</sup> are each independently a carbon atom or a nitrogen atom,

----- is a single bond or a double bond, and

the other symbols have the same meanings as those defined in claim 1.

5. (withdrawn) The compound according to claim 4, which is represented by formula (I-3)



wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently a hydrogen atom or a substituent, and R<sup>4</sup> and R<sup>5</sup>, and/or R<sup>6</sup> and R<sup>7</sup> may be together with their binding carbon atom to form a cyclic group which may have a substituent(s);

ring A<sup>4</sup> is a cyclic group which may have a substituent(s);

X<sup>1</sup> and Z<sup>1</sup> are each independently a single bond, C1-3 alkylene which may have a substituent(s), C2-3 alkenylene which may have a substituent(s) or C2-3 alkynylene which may have a substituent(s);

Y<sup>1</sup> is -C(=O)-, -C(=S)-, -C(=O)NR<sup>103</sup>-, -SO<sub>2</sub>-, -C(=O)O- or SO<sub>2</sub>NR<sup>103</sup>-, in which R<sup>103</sup> is a hydrogen atom or a substituent,

the sum of the number of substituents represented by R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> is 4 or less, and

the other symbols have the same meanings as those defined in claim 1.

6. **(withdrawn)** The compound according to claim 5, wherein R<sup>4</sup> and R<sup>5</sup> are simultaneously substituents, or R<sup>4</sup> and R<sup>5</sup> are together with their binding carbon atom to form a cyclic group which may have a substituent(s).

7. **(withdrawn)** The compound according to claim 5, wherein R<sup>3</sup> is a substituent.

8. **(withdrawn)** The compound according to claim 5, wherein R<sup>6</sup> and R<sup>7</sup> are simultaneously substituents, or R<sup>6</sup> and R<sup>7</sup> are together with their binding carbon atom to form a cyclic group which may have a substituent(s).

9. **(withdrawn)** The compound according to claim 5, wherein  $R^3$  is a mono-heterocyclic ring.

10. **(withdrawn)** The compound according to claim 5, wherein B is a C3-10 mono-, or di-carbocyclic ring which may have a substituent(s) or a 3-10 membered mono-, or di-heterocyclic ring which may have a substituent(s).

11. **(withdrawn)** The compound according to claim 5, wherein ring  $A^4$  is a C3-10 mono-, or di-carbocyclic ring which may have a substituent(s) or a 3-10 membered mono-, or di-heterocyclic ring which may have a substituent(s).

12. **(withdrawn)** The compound according to claim 5, wherein  $Y^1$  is  $-C(=O)-$  or  $-C(=O)NR^{103}-$ .

13. **(withdrawn)** The compound according to claim 4, which is selected from

(1) N-(3,5-dimethylphenyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,

(2) N-(3-methylphenyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,

(3) N-(3,5-dimethylphenyl)-6-methoxy-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,

- (4) 6-methoxy-N-(3-methylphenyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (5) 6-methoxy-N-[2-(trifluoromethyl)phenyl]-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (6) N-(3,5-dichlorophenyl)-6-methoxy-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (7) 1-(3-fluorophenyl)-N-phenyl-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (8) 1-(3-fluorophenyl)-N-(3-methylphenyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (9) N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (10) 2-acetyl-1-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,
- (11) 2-({[5-(trifluoromethyl)pyridin-2-yl]thio}acetyl)-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,
- (12) 2-({[2,5-dimethoxyphenyl]thio}acetyl)-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,
- (13) 6-methoxy-1-(trifluoromethyl)-2-({[5-(trifluoromethyl)pyridin-2-yl]thio}acetyl)-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,
- (14) 2-({[2,5-dimethoxyphenyl]thio}acetyl)-6-methoxy-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,

- (15) 6-methoxy-N-(3-methylphenyl)-1-(trifluoromethyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (16) N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-1,9-dihydrospiro[ $\beta$ -carboline-4,1'-cyclopropane]-2(3H)-carboxamide,
- (17) rac-(1R,3S)-N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-3-methyl-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (18) rac-(1R,3R)-N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-3-methyl-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (19) N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-6-(trimethylsilyl)-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (20) N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-4,4-dimethyl-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxamide,
- (21) 2-acetyl-1-(3-fluorophenyl)-1,2,3,9-tetrahydrospiro[ $\beta$ -carboline-4,1'-cyclopropane],
- (22) 2-(benzylsulfonyl)-1-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,
- (23) rac-(1R,3R)-2-acetyl-1-(3-fluorophenyl)-3-methyl-2,3,4,9-tetrahydro-1H- $\beta$ -carboline,
- (24) methyl 1-(3-fluorophenyl)-3,3-dimethyl-1,3,4,9-tetrahydro-2H- $\beta$ -carboline-2-carboxylate, and

(25) N-(3,5-dimethylphenyl)-8-(3-fluorophenyl)-5,6,8,9-tetrahydro-7H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridine-7-carboxamide.

14. **(currently amended):** A pharmaceutical composition comprising the compound represented by formula ~~(I)~~(1-3-4) according to claim 23, a salt thereof[.].

15. -18. **(canceled).**

19. **(withdrawn)** A method for prevention and/or treatment for a central nervous system, a respiratory system disease and/or a digestive disease in mammals, comprising administering to a mammal an effective amount of the compound represented by formula (I) according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.


20. **(withdrawn)** A pharmaceutical composition combining the compound represented by formula (I) according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and one kind or more kind selected from antianxiety drugs, antidepressant drugs, antiparkinson drugs, therapeutic drugs for schizophrenia, antiepileptic drugs, therapeutic drugs for asthma, therapeutic drugs for peptic ulcer, adjustive drugs for gastrointestinal function, antidiarrheals, evacuants, antihypertensive drugs, antiarrhythmic drugs, inotropic drugs and therapeutic drugs for urination disorder.



21. **(withdrawn)** A method for prevention and/or treatment for a mitochondrial benzodiazepine receptor mediated disease in mammals, which comprises administering to a mammal an effective amount of the compound represented by formula (I) according to claim 23, a salt thereof, an N-oxide, a solvate or a prodrug thereof.

22. **(canceled)**

23. **(previously presented):** A compound represented by formula (I-3-4):



wherein,

ring A<sup>3</sup> is benzene, pyridine, pyrimidine or pyrazine;

ring A<sup>4</sup> is benzene which may be substituted with 1 to 4 substituent(s) optionally selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, hydroxyl, C1-8 alkoxy, amino, NR<sup>104</sup>R<sup>105</sup>, carboxyl, C1-6 alkoxy carbonyl, nitro, cyano, a halogen atom, oxo, acyl, formyl and tri(C1-6 alkyl)silyl;

R<sup>104</sup> and R<sup>105</sup> are each independently a hydrogen atom or C1-8 alkyl;

R<sup>1</sup> is C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, hydroxyl, C1-8 alkoxy, mercapto, C1-8 alkylthio, amino, NR<sup>104</sup>R<sup>105</sup>, carboxyl, C1-6 alkoxycarbonyl, nitro, cyano, a halogen atom, oxo, acyl, formyl or tri(C1-6 alkyl)silyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>6</sup> and R<sup>7</sup> represent a hydrogen atom ;

R<sup>4</sup> and R<sup>5</sup> are together with their binding carbon atom to form C3-8 cycloalkyl;

X<sup>1</sup> and Z<sup>1</sup> represent a single bond;

Y<sup>1</sup> is -C(=O)-, -C(=O)NR<sup>103</sup>-, [[-,]] -SO<sub>2</sub>-, -C(=O)O- or SO<sub>2</sub>NR<sup>103</sup>;

R<sup>103</sup> is a hydrogen atom;

B is C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl which may be substituted with 1 to 4 substituent(s) optionally selected from hydroxyl, mercapto, amino, carboxyl, nitro, cyano, mono- or di-C1-6 alkylamino, C1-6 alkoxy, C1-6 alkylcarbonyloxy, C1-6 alkylthio, a halogen atom, acyl, or benzene which may be substituted with 1 to 4 substituent(s) optionally selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, hydroxyl, C1-8 alkoxy, amino, NR<sup>104</sup>R<sup>105</sup>, carboxyl, C1-6 alkoxycarbonyl, nitro, cyano, a halogen atom, oxo, acyl, formyl and tri(C1-6 alkyl)silyl; and

t is 0 or an integer 1 to 5, a salt thereof.

24. **(previously presented):** The compound according to claim 23, wherein ring A<sup>3</sup> is a benzene; Y<sup>1</sup> is -C(=O)- or -C(=O)NR<sup>103</sup>.

25. **(previously presented):** The compound according to claim 23, which is selected from

(1) N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-1,9-dihydrospiro[ $\beta$ -carboline-4,1'-cyclopropane]-2(3H)-carboxamide, and

(2) 2-acetyl-1-(3-fluorophenyl)-1,2,3,9-tetrahydrospiro[ $\beta$ -carboline-4,1'-cyclopropane].

26. (currently amended): A method for treatment for irritable bowel syndrome ~~mitochondrial benzodiazepine receptor mediated disease~~ in a mammal, which comprises administering an effective amount of the compound represented by formula (I-3-4) according to claim 23, or a salt thereof, to a mammal in need thereof.

27. - 29. (canceled).